Research
Hormonal
GLP-1 receptor agonists may increase the risk of acute pancreatitis and pancreatic cancer, although meta-analyses have sometimes excluded this risk, and the evidence remains inconclusive with conflicting study results.
Be aware of symptoms of pancreatitis (severe abdominal pain, nausea, vomiting) while on GLP-1 medications. While the absolute risk is debated, it is a known potential side effect. Report any persistent abdominal pain to your doctor immediately.
ModerateQualifiesMEDIUM confidence
some studies have associated the use of GLP-1RA with an increased risk of pancreatitis and pancreatic cancer, although the findings in this matter are not conclusive... Although a meta-analysis conducted in 2020 excluded the existence of an increased risk of pancreatic cancer and acute pancreatitis following the use of GLP-1RA, the consistently elevated levels of amylase and pancreatic lipase observed in many studies still appear concerning.
Why this rating
Conflicting evidence between individual studies showing elevated enzymes and meta-analyses finding no significant risk increase.
Source
GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
Patrycja Kupnicka et al. · Pharmaceuticals · 2024
DOI 10.3390/ph17111470
narrative_reviewCited 15×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists lower serum TSH levels in patients with Type 2 Diabetes, particularly those who experience weight loss, without necessarily changing free thyroxine (FT4) levels, suggesting a mechanism involving central nervous system GLP-1 receptors or improved thyroid hormone sensitivity.Good
- Long-term use of GLP-1 receptor agonists (specifically liraglutide, dulaglutide, and exenatide) is associated with an increased risk of thyroid tumors, including C-cell hyperplasia and medullary thyroid carcinoma, primarily through the stimulation of GLP-1 receptors on thyroid C cells leading to calcitonin gene expression and cellular hyperplasia.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →